Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 19:12:e40653.
doi: 10.2196/40653.

The Global Prevalence of Nonalcoholic Fatty Liver Disease and its Association With Cancers: Systematic Review and Meta-Analysis

Nor Asiah Muhamad #  1 , Nur Hasnah Maamor #  1 , Fatin Norhasny Leman  1 , Zuraifah Asrah Mohamad  2 , Sophia Karen Bakon  2 , Mohd Hatta Abdul Mutalip  3 , Izzah Athirah Rosli  1 , Tahir Aris  2 , Nai Ming Lai  4 , Muhammad Radzi Abu Hassan  5
Affiliations
Review

The Global Prevalence of Nonalcoholic Fatty Liver Disease and its Association With Cancers: Systematic Review and Meta-Analysis

Nor Asiah Muhamad et al. Interact J Med Res. .

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is one of the common causes of chronic liver disease globally. Obesity, metabolic diseases, and exposure to some environmental agents contribute to NAFLD. NAFLD is commonly considered a precursor for some types of cancers. Since the leading causes of death in people with NAFLD are cardiovascular disease and extrahepatic cancers, it is important to understand the mechanisms of the progression of NAFLD to control its progression and identify its association with extrahepatic cancers. Thus, this review aims to estimate the global prevalence of NAFLD in association with the risk of extrahepatic cancers.

Objective: We aimed to determine the prevalence of various cancers in NAFLD patients and the association between NAFLD and cancer.

Methods: We searched PubMed, ProQuest, Scopus, and Web of Science from database inception to March 2022 to identify eligible studies reporting the prevalence of NAFLD and the risk of incident cancers among adult individuals (aged ≥18 years). Data from selected studies were extracted, and meta-analysis was performed using random effects models to obtain the pooled prevalence with the 95% CI. The quality of the evidence was assessed with the Newcastle-Ottawa Scale.

Results: We identified 11 studies that met our inclusion criteria, involving 222,523 adults and 3 types of cancer: hepatocellular carcinoma (HCC), breast cancer, and other types of extrahepatic cancer. The overall pooled prevalence of NAFLD and cancer was 26% (95% CI 16%-35%), while 25% of people had NAFLD and HCC (95% CI 7%-42%). NAFLD and breast cancer had the highest prevalence out of the 3 forms of cancer at 30% (95% CI 14%-45%), while the pooled prevalence for NAFLD and other cancers was 21% (95% CI 12%-31%).

Conclusions: The review suggests that people with NAFLD may be at an increased risk of cancer that might not affect not only the liver but also other organs, such as the breast and bile duct. The findings serve as important evidence for policymakers to evaluate and recommend measures to reduce the prevalence of NAFLD through lifestyle and environmental preventive approaches.

Trial registration: PROSPERO CRD42022321946; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=321946.

Keywords: NAFL; NAFLD; cancer; cancers; carcinoma; extrahepatic; fatty liver; liver; nonalcoholic fatty liver; nonalcoholic fatty liver disease; prevalence.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
Map of study sites in the included articles.
Figure 2
Figure 2
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram of the selection process.
Figure 3
Figure 3
Forest plot of overall prevalence of fatty liver and cancer [29-39].
Figure 4
Figure 4
Forest plot of overall prevalence of fatty liver and hepatocellular carcinoma [31,33-35,38].
Figure 5
Figure 5
Forest plot of overall prevalence of fatty liver and breast cancer [30,32,37,39].
Figure 6
Figure 6
Forest plot of overall prevalence of fatty liver and other cancers [29,36].
See this image and copyright information in PMC

References

    1. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021 Jun 05;397(10290):2212–2224. doi: 10.1016/S0140-6736(20)32511-3.S0140-6736(20)32511-3 - DOI - PubMed
    1. Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease: Pathophysiology and management. Gastroenterol Clin North Am. 2016 Dec;45(4):639–652. doi: 10.1016/j.gtc.2016.07.003. https://europepmc.org/abstract/MED/27837778 S0889-8553(16)30060-7 - DOI - PMC - PubMed
    1. Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2012 May;5(3):199–207. doi: 10.1177/1756283X11430859. https://journals.sagepub.com/doi/10.1177/1756283X11430859?url_ver=Z39.88... 10.1177_1756283X11430859 - DOI - DOI - PMC - PubMed
    1. Zhou L, Wang J, Yu S, Wu G, Wei Q, Deng Y, Wu X, Cui X, Dietrich CF. Artificial intelligence in medical imaging of the liver. World J Gastroenterol. 2019 Feb 14;25(6):672–682. doi: 10.3748/wjg.v25.i6.672. https://www.wjgnet.com/1007-9327/full/v25/i6/672.htm - DOI - PMC - PubMed
    1. Majumder S, Deen MJ. Smartphone sensors for health monitoring and diagnosis. Sensors (Basel) 2019 May 09;19(9):2164. doi: 10.3390/s19092164. https://www.mdpi.com/resolver?pii=s19092164 s19092164 - DOI - PMC - PubMed